{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:34:57Z","timestamp":1791826497333,"version":"4.3.4"},"reference-count":19,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"<jats:p>Primary immune regulatory disorders (PIRD) comprise a heterogeneous group of monogenic disorders that impact homeostatic control of inflammation and immune tolerance. Patients with a PIRD typically present to medical care with symptoms of autoimmunity or hyperinflammation as the dominant\n clinical feature, symptoms that include fever, rash, lymphadenopathy, organomegaly, arthritis, and colitis are commonplace. Notably, PIRDs are a distinct entity from primary immune deficiency disorders (PIDD), which are primarily defined by a qualitative or quantitative defect in immunity,\n which manifests as a susceptibility to recurrent infections. PIDDs and PIRDs can be challenging to differentiate because the clinical presentations can be similar. Red flags for PIRDs include multiple autoimmune diagnoses in the same patient, chronic lymphadenopathy, hepatomegaly, and\/or splenomegaly,\n chronic colitis, hemophagocytic lymphohistiocytosis (HLH), Epstein Barr virus (EBV) susceptibility, recurrent or persistent fever, vasculitis, and sterile inflammation. For simplicity in this brief review, we limit our discussion of PIRDs to the following categories multiple autoimmune diseases,\n immune dysregulation with colitis, disorders with HLH and\/or EBV susceptibility, autoinflammatory syndromes, type 1 interferonopathies, and disorders of sterile inflammation. Diagnosing a PIRD requires a broad immune evaluation for both immune system deficiencies and inflammation, along with\n genetic testing. Given the complex nature of these diseases, treatment often requires a team of subspecialists. Treatment, depending on the specific diagnosis, may be somewhat empiric with nonspecific immune modulators, symptom-directed therapies, and, in severe cases, hematopoietic stem cell\n transplantation; however, with the increasing number of biologics available, we are often able to use targeted immune therapy or even gene therapy.<\/jats:p>","DOI":"10.2500\/aap.2024.45.240070","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:31:59Z","timestamp":1726720319000},"page":"332-339","source":"Crossref","is-referenced-by-count":15,"title":["Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs)"],"prefix":"10.2500","volume":"45","author":[{"given":"Cody S.","family":"Nelson","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn H.","family":"Baloh","sequence":"additional","affiliation":[{"name":"From the Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fimmu.2020.00239","article-title":"Hematopoietic cell transplantation in patients with primary immune regulatory disorders (PIRD): a Primary Immune Deficiency Treatment Consortium (PIDTC) survey","volume":"11","author":"Chan","year":"2020","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-022-02249-1","article-title":"Primary immune regulatory disorders: undiagnosed needles in the haystack?","volume":"17","author":"Flinn","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pop.2022.12.001","article-title":"Inborn errors of immunity","volume":"50","author":"Baloh","year":"2023","journal-title":"Prim Care"},{"key":"B4","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/ACI.0000000000000689","article-title":"Primary immune regulatory disorders: a growing universe of immune dysregulation","volume":"20","author":"Chan","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1007\/s10875-022-01352-z","article-title":"The 2022 update of IUIS Phenotypical Classification for Human Inborn Errors of Immunity","volume":"42","author":"Bousfiha","year":"2022","journal-title":"J Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the International Union of Immunological Societies Expert Committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.2500\/aap.2024.45.240058","article-title":"Immunodysregulation in immunodeficiency","volume":"45","author":"Chang","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1399-5448.2009.00530.x","article-title":"Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register","volume":"11","author":"Wiedemann","year":"2010","journal-title":"Pediatr Diabetes"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1279201","DOI":"10.3389\/fimmu.2023.1279201","article-title":"Too much of a good thing: a review of primary immune regulatory disorders","volume":"14","author":"Tsilifis","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jaci.2018.10.026","article-title":"Tregopathies: monogenic diseases resulting in regulatory T-cell deficiency","volume":"142","author":"Cepika","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3389\/fped.2019.00353","article-title":"Inborn errors of immunity with immune dysregulation: from bench to bedside","volume":"7","author":"Delmonte","year":"2019","journal-title":"Front Pediatr"},{"key":"B12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jaci.2020.09.019","article-title":"Pediatric recurrent fever and autoinflammation from the perspective of an allergist\/immunologist","volume":"146","author":"Broderick","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B13","first-page":"45","article-title":"Diagnostic tests for primary immunodeficiency disorders (PID): Classic and genetic testing","author":"Klangkalya","year":"2024","journal-title":"Allergy Asthma Proc"},{"key":"B14","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"crossref","first-page":"692219","DOI":"10.3389\/fimmu.2021.692219","article-title":"The use of biologic modifiers as a bridge to hematopoietic cell transplantation in primary immune regulatory disorders","volume":"12","author":"Arnold","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaip.2018.12.017","article-title":"Mechanism-based precision therapy for the treatment of primary immunodeficiency and primary immunodysregulatory diseases","volume":"7","author":"Leiding","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"770077","DOI":"10.3389\/fped.2022.770077","article-title":"STAT3 gain-of-function syndrome","volume":"10","author":"Vogel","year":"2023","journal-title":"Front Pediatr"},{"key":"B19","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/eji.202149210","article-title":"Towards gene therapy for IPEX syndrome","volume":"52","author":"Borna","year":"2022","journal-title":"Eur J Immunol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000005\/art00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T04:33:42Z","timestamp":1726720422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.240070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9,1]]}},"alternative-id":["1088-5412(20240901)45:5L.332;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.240070","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}